Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab
Barbora Bačová, Zuzana Kohutová, Ivana Zubata, Ľubica Gahérová, Petr Kučera, Tomáš Heizer, Marcela Mikesova, Tomáš Karel, Jan Novák
Topics & Concepts
IbrutinibRituximabMedicineImmunologySerologyImmune systemHematologyBruton's tyrosine kinaseB cellChronic lymphocytic leukemiaInternal medicineAntibodyLeukemiaTyrosine kinaseReceptorChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchSARS-CoV-2 and COVID-19 Research